SEARCH

SEARCH BY CITATION

References

  • 1
    Gorman C, Leandro M, Isenberg D. B cell depletion in autoimmune disease. Arthritis Res Ther 2003; 5: S1721.
  • 2
    Patriarca F, Medeot M, Isola M, Battista ML, Sperotto A, Pipan C, Toffoletti E, Dozzo M, Michelutti A, Gregoraci G, Geromin A, Cerno M, Savignano C, Rinaldi C, Barbone F, Fanin R. Prognostic factors and outcome of Epstein-Barr virus DNAemia in high-risk recipients of allogeneic stem cell transplantation treated with preemptive rituximab. Transpl Infect Dis 2013; 15: 259267.
  • 3
    Faguer S, Kamar N, Guilbeaud-Frugier C, Fort M, Modesto A, Mari A, Ribes D, Cointault O, Lavayssière L, Guitard J, Durand D, Rostaing L. Rituximab therapy for acute humoral rejection after kidney transplantation. Transplantation 2007; 83: 12771280.
  • 4
    Nojima M, Yoshimoto T, Nakao A, Itahana R, Kyo M, Hashimoto M, Shima H. Sequential blood level monitoring of basiliximab during multisession plasmapheresis in a kidney transplant recipient. Transplant Proc 2005; 37: 875878.
  • 5
    McDonald V, Manns K, Mackie IJ, Machin SJ, Scully MA. Rituximab pharmacokinetics during the management of acute idiopathic thrombotic thrombocytopenic purpura. J Thromb Haemost 2010; 8: 12011208.
  • 6
    Blasco H, Lalmanach G, Godat E, Maurel MC, Canepa S, Belghazi M, Paintaud G, Degenne D, Chatelut E, Cartron G, Le Guellec C. Evaluation of a peptide ELISA for the detection of rituximab in serum. J Immunol Methods 2007; 325: 127139.